Scilex Holding (SCLX) Non-Current Assets (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Non-Current Assets of $1.5 million for Q1 2026, up 1201.68% year-over-year from $119000.0 in Q1 2025, and up 196.18% on a QoQ basis from $523000.0 in Q4 2025.
Scilex Holding (SCLX) Non-Current Assets (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Non-Current Assets for 7 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 1201.68% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 1201.68% YoY), while the FY2025 annual figure was $523000.0, up 339.5% from the prior year.
- Non-Current Assets came in at $1.5 million for Q1 2026 at Scilex Holding, up from $523000.0 in the prior quarter.
- The five-year high for Non-Current Assets was $141.7 million in Q2 2022, with the low at $119000.0 in Q4 2024.
- Average Non-Current Assets over 5 years is $23.6 million, with a median of $944000.0 recorded in 2022.
- Across the five-year window, Non-Current Assets plunged 99.89% in 2023 and jumped 4814.46% in 2024, its largest moves.
- Year by year, Non-Current Assets stood at $944000.0 in 2022, then declined by 4.98% to $897000.0 in 2023, then tumbled by 86.73% to $119000.0 in 2024, then surged by 339.5% to $523000.0 in 2025, then soared by 196.18% to $1.5 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $1.5 million, $523000.0, and $119000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 61.74 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 141.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 102.93 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 84.40 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 1.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.55 Mn |
| Dec 31, 2025 | 523,000.00 |
| Sep 30, 2025 | 119,000.00 |
| Jun 30, 2025 | 119,000.00 |
| Mar 31, 2025 | 119,000.00 |
| Dec 31, 2024 | 119,000.00 |
| Sep 30, 2024 | 8.16 Mn |
| Jun 30, 2024 | 2.90 Mn |
| Mar 31, 2024 | 1.08 Mn |
| Dec 31, 2023 | 897,000.00 |
| Sep 30, 2023 | 166,000.00 |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 153,000.00 |
| Dec 31, 2022 | 944,000.00 |
| Sep 30, 2022 | 101.29 Mn |
| Jun 30, 2022 | 141.69 Mn |
| Mar 31, 2022 | 140.45 Mn |
| Dec 31, 2021 | 538,000.00 |
| Sep 30, 2021 | 139.41 Mn |
| Jun 30, 2021 | 139.41 Mn |